The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study

• DOI: 10.1007/s10554-011-9949-4
• Publication Date: 2011-10-03T08:58:50Z
• Authors: Edward V. R. DiBella; Jacob U. Fluckiger; Liyong Chen; Tae Ho Kim; Nathan A. Pack; Brian Matthews; Ganesh Adluru; Tiffany Priester; Suman Kuppahally; Ronny Jiji; Chris McGann; Sheldon E. Litwin
• Keywords: Regadenoson; Coronary vasodilator

The A2A receptor agonist, regadenoson, is increasingly used as a vasodilator during nuclear myocardial perfusion imaging. Regadenoson administered single, fixed dose. Given the frequency of obesity in patients with symptoms heart disease, it important to know whether dose regadenoson produces maximal coronary hyperemia subjects widely varying body size. Thirty (12 female, 18 male, mean BMI 30.3 ± 6.5, range 19.6–46.6) were imaged on 3T magnetic resonance scanner. Imaging saturation recovery radial turboFLASH sequence was done first at rest, then adenosine infusion (140 μg/kg/min) and 30 min later (0.4 mg/5 ml bolus). A 5 cc/s injection Gd-BOPTA for each sequence, doses 0.02, 0.03 mmol/kg, respectively. Analysis upslope time-intensity curves quantitative processing obtain reserve (MPR) values performed vasodilator. tissue upslopes matched closely (y = 1.1x + 0.03, r 0.9). Mean MPR 2.3 0.6 2.4 0.9 (p 0.14). There good agreement between measured − 0.06, 0.7). both agents tended be lower increased. no complications administration either agent. produced fewer side effects. Fixed weight adjusted produce similar measures wide sizes. potentially useful stress MRI studies.